By selecting for antibodies that show minimal cross-reactivity in preclinical models, researchers can enhance the likelihood of successful therapeutic outcomes; Personalized Medicine Approaches: Tailoring TCRL antibodies to individual patients based on their specific MHC profiles and tumor antigen expression can improve specificity and reduce the risk of off-target effects; Combination Therapies: Using TCRL antibodies in conjunction with other therapies (e.g., checkpoint inhibitors) may help to enhance specificity while also improving overall therapeutic efficacy. The gene discussed is HLA-C; the disease is neoplasm.